ClinicalTrials.gg
RecruitingNCT07327229CLINCH-2Updated Jul 29, 2026

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 1/2 interventional study of ATG-022 and pembrolizumab/KEYTRUDA® in Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Antengene Biologics Limited. Recruiting at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Antengene Biologics Limited · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Read the detailed description

This is a phase Ib/II Study of ATG-022 plus pembrolizumab with/without chemotherapy in participants with CLDN 18.2-positive, HER2-negative, PD-L1 positive (CPS≥1), unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Both the intervention of ATG022 + Pembrolizumab (A+P) and the intervention of ATG-022 + pembrolizumab + chemotherapy (CAPOX regimen, A+P+C) consist of a Ib and II phase.

Participants with CLDN 18.2-positive, HER2-negative, PD-L1 positive (CPS≥1) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and having progressed on or after at least one prior systemic therapy, will be enrolled in the intervention of A + P.

Participants with CLDN 18.2-positive, HER2-negative, PD-L1 positive (CPS≥1) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and having not received any prior systemic therapy, will be enrolled in the intervention of A + P + C. The study will be firstly initiated from Ib of the intervention of A+P. The initiation of the intervention of A+P+C will be based on the clinical data of A+P

02

Conditions studied

  • Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Antengene Biologics Limited is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study-specific procedures, sampling, and analyses.
  2. Aged ≥18 years as of the date of consent.
  3. Histological or cytological confirmation of gastric cancer or gastroesophageal junction adenocarcinoma with CLDN 18.2 positive, -negative and positive expression.
  4. sample within 36 months prior to participating in the study or newly obtained biopsy of a tumor lesion not previously irradiated should be provided for testing of CLDN 18.2 and PD-L1 expression for determining the criteria.
  5. At least 1 per (RECIST) v1.1 by investigators.
  6. Estimated of a minimum of 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Known active central nervous system and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required treatment for at least 14 days before the first dose of study intervention.
  2. Prior exposure to CLDN 18.2 ADC, CLDN 18.2 chimeric antigen receptor T-cell immunotherapy or agents containing MMAE.
  3. Prior systemic anticancer therapy including agents within 4 weeks before the first dose of study treatment or within a period during which the investigational product or systemic anticancer treatment has not been cleared from the body (e.g., a period of 5 'halflives'), whichever is the most appropriate as judged by the investigator.
  4. Received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.
  5. Prior radiotherapy within 4 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids. Two weeks or fewer of palliative radiotherapy for non- central nervous system disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention
  6. Prior a live or within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  7. Prior major surgery (excluding placement of vascular access) within 28 days of the first dose of study treatment or minor surgical procedures≤7 days. No waiting is required following implantable port and catheter placement.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    ATG-022+pembrolizumab/KEYTRUDA®

    Drug: ATG-022 · Drug: pembrolizumab/KEYTRUDA®

  • Active comparator
    ATG-022+pembrolizumab/KEYTRUDA®+CAPOX

    Drug: ATG-022 · Drug: pembrolizumab/KEYTRUDA® · Drug: CAPOX

Interventions

  • 1.8mg/kg Q3W, every 21 days as one cycle

  • Drugpembrolizumab/KEYTRUDA®

    Drug page: Pembrolizumab

    20mg Q3W, every 21 days as one cycle

  • DrugCAPOX

    Standard Dose level for CAPOX: Capecitabine 1000 mg/m2 PO BID on Day 1-14, Oxaliplatin 130 mg/m2 IV on Day 1, Cycled every 21 days (3 weeks) for 8 cycles.

06

What researchers measure

Primary outcomes

  1. AEs and SAEs

    Time frame: 12 months after the last subject enrolled

  2. DLT

    Dose Limiting Toxicity

    Time frame: Up to 21 Days

  3. RP2D

    RP2D= Recommended Phase 2 Dose

    Time frame: Up to 21 Days

Secondary outcomes

  1. ORR

    Overall Response Rate

    Time frame: 12 months after the last subject enrolled

  2. DOR

    Duration of Response

    Time frame: 12 months after the last subject enrolled

  3. PFS

    Progression Free Survival

    Time frame: 12 months after the last subject enrolled

  4. Plasma concentration of ATG-022 and derived PK paramete

    To characterize the PK of ATG-022

    Time frame: One year after last patient first dose

07

Study locations

26 of 30 sites recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui, China
    Recruiting
    • Gang Wang · Contact
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Kangsheng Gu · Contact
  • Beijing Cancer hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Lin Shen, MD · Contact
  • Fujian Provincial Cnacer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Rongbo Lin · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
    • Jiayi Li · Contact
  • Gansu Provincial Cnacer Hospital
    Lanzhou, Gansu, China
    Not yet recruiting
    • Yuhua Liu · Contact
  • Cancer Institute&Hospital Chinese Academy of Medical Sciences
    Langfang, Hebei, China
    Not yet recruiting
    • Yongkun Sun · Contact
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Qun Zhao · Contact
  • Anyang Tumor Hospital
    Anyang, Henan, China
    Recruiting
    • Jin Xia · Contact
  • The First Affiliated Hospital of Henan Medical Hospital
    Xinxiang, Henan, China
    Recruiting
    • Liuzhong Yang · Contact
  • Henan Cnacer Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
    • Xiaobing Chen · Contact
  • The First Affiliated Hospital of Zhenghzou University
    Zhengzhou, Henan, China
    Recruiting
    • Yanru Qin · Contact
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
    Recruiting
    • Xinjun Liang · Contact
  • Tongji Medical College of HUST
    Wuhan, Hubei, China
    Recruiting
    • Xianglin Yuan · Contact
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Xiaofeng Chen · Contact
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
    • zhixiang Zhuang · Contact
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu, China
    Not yet recruiting
    • Yuan Yuan · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Xiaodong Peng · Contact
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Recruiting
    • funan Liu · Contact
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia, China
    Recruiting
    • Ping Chen · Contact
  • Jinan Central Hospital
    Jinan, Shandong, China
    Recruiting
    • Meili Sun · Contact
  • Shandong Cancer Hospital &Institue
    Jinan, Shandong, China
    Recruiting
    • Changzheng Li · Contact
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
    Recruiting
    • Jing LV · Contact
  • Tongren Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Jianjun Zhang · Contact
  • Shanxi provincial cancer hospital
    Taiyuan, Shanxi, China
    Recruiting
    • Jinfeng Ma, MD · Contact
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
    Recruiting
    • Yusheng Wang · Contact
  • The First Affiliated Hospital of XI'AN Jiaotong University
    Xi’an, Shanxi, China
    Recruiting
    • Ying Kong · Contact
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Li Zheng, MD · Contact
  • Tianjin Medical Universuty Cancer Institute & Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
    • Ting Deng · Contact
  • The First Affiliated Hospital of Xiamen University
    Wenzhou, Zhejiang, China
    Recruiting
    • Yin Jin · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Jan 8, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Apr 30, 2029
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07327229
Lead sponsor
Antengene Biologics Limited
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Feb 27, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Jul 29, 2026

Study contacts

felix li
Contact
felix.li@antengene.com
182 05191049
Jasmine Sun
Contact
jasmine.sun@antengene.com
021-32501095

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ATG-022

Start the discussion